TABLE II.

Selected ongoing immunotherapy studies in soft-tissue sarcoma (STS)

ClinicalTrials.gov ID	Details
NCT03463408	Study title: Immunotherapy + radiation in resectable soft tissue sarcoma
	Phase: I	Status: Recruiting	Location: U.S.A.
	Interventions: Ipilimumab, nivolumab, and radiation
NCT03116529	Study title: Neoadjuvant durvalumab and tremelimumab plus radiation for high risk soft-tissue sarcoma (NEXIS)
	Phase: I/II	Status: Recruiting	Location: U.S.A.
	Interventions: Durvalumab, tremelimumab, and radiation
NCT02815995	Study title: Multi-arm study to test the efficacy of immunotherapeutic agents in multiple sarcoma subtypes
	Phase: II	Status: Active, not recruiting	Location: U.S.A.
	Interventions: Durvalumab and tremelimumab
NCT03138161	Study title: SAINT: trabectedin, ipilimumab and nivolumab as first line treatment for advanced soft tissue sarcoma
	Phase: I/II	Status: Recruiting	Location: U.S.A.
	Interventions: Trabectedin, ipilimumab, and nivolumab
NCT02609984	Study title: Trial of CMB305 and atezolizumab in patients with sarcoma (IMDZ-C232)
	Phase: II	Status: Active, not recruiting	Location: U.S.A.
	Interventions: Atezolizumab and CMB305
NCT03851614	Study title: Basket combination study of inhibitors of DNA damage response, angiogenesis and programmed death ligand 1 in patients with advanced solid tumors (DAPPER)
	Phase: II	Status: Recruiting	Location: Canada
	Interventions: Durvalumab and olaparib–cediranib
NCT02879162	Study title: Durvalumab and tremelimumab in patients with advanced rare tumours
	Phase: II	Status: Recruiting	Location: Canada
	Interventions: Durvalumab and tremelimumab
NCT03141684	Study title: Atezolizumab in treating patients with newly diagnosed and metastatic alveolar soft part sarcoma that cannot be removed by surgery
	Phase: II	Status: Recruiting	Location: U.S.A.
	Interventions: Atezolizumab
NCT03450122	Study title: Modified T cells, chemotherapy, and aldesleukin with or without LV305 and CMB305 in treating participants with advanced or recurrent sarcoma
	Phase: I	Status: Active, not recruiting	Location: U.S.A.
	Interventions: Modified T cells; LV305 or CMB305
NCT00902044	Study title: HER2 chimeric antigen receptor expressing T cells in advanced sarcoma
	Phase: I	Status: Recruiting	Location: U.S.A.
	Interventions: Autologous HER2-specific T cells; fludarabine, cyclophosphamide
NCT02423863	Study title: In situ, autologous therapeutic vaccination against solid cancers with intratumoral Hiltonol (poly-ICLC)
	Phase: II	Status: Recruiting	Location: U.S.A.
	Interventions: Hiltonol